IXICO announces its unaudited interim results for the six months ended 31 March 2015.
- Extension of two clinical trials in Huntington’s Disease, valued at approximately £2.5m over three years
- VirtualScopics alliance delivering commercial value
- Partner in the European Prevention of Alzheimer’s dementia Initiative (EPAD)
- Strengthened capabilities, technology and IP on healthcare data analytics
- Financial performance underpinned by strong revenue growth of 36% to £1.6m